Jeffery L. Kutok
Net Worth
Last updated:
What is Jeffery L. Kutok net worth?
The estimated net worth of Dr. Jeffery L. Kutok is at least $2,417,806 as of 9 Aug 2022. He owns shares worth $138,062 as insider, has earned $23,824 from insider trading and has received compensation worth at least $2,255,920 in Epizyme, Inc..
What is the salary of Jeffery L. Kutok?
Dr. Jeffery L. Kutok salary is $563,980 per year as Chief Scientific Officer in Epizyme, Inc..
How old is Jeffery L. Kutok?
Dr. Jeffery L. Kutok is 58 years old, born in 1967.
What stocks does Jeffery L. Kutok currently own?
As insider, Dr. Jeffery L. Kutok owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Epizyme, Inc. (EPZM) | Chief Scientific Officer | 94,563 | $1.46 | $138,062 |
What does Epizyme, Inc. do?
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Jeffery L. Kutok insider trading
Epizyme, Inc.
Dr. Jeffery L. Kutok has made 3 insider trades between 2021-2022, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 380,000 units of EPZM stock on 9 Aug 2022. As of 9 Aug 2022 he still owns at least 94,563 units of EPZM stock.
Epizyme key executives
Epizyme, Inc. executives and other stock owners filed with the SEC:
- Dr. Jeffery L. Kutok (58) Chief Scientific Officer
- Dr. Shefali Agarwal M.D., MPH (51) Executive Vice President and Chief Medical & Devel. Officer
- Mr. Grant C. Bogle (67) Pres, Chief Executive Officer, Principal Financial Officer & Director
- Mr. Matthew E. Ros (58) Advisor